JP5198259B2 - 網膜剥離を治療するための組成物およびその製造方法 - Google Patents
網膜剥離を治療するための組成物およびその製造方法 Download PDFInfo
- Publication number
- JP5198259B2 JP5198259B2 JP2008511711A JP2008511711A JP5198259B2 JP 5198259 B2 JP5198259 B2 JP 5198259B2 JP 2008511711 A JP2008511711 A JP 2008511711A JP 2008511711 A JP2008511711 A JP 2008511711A JP 5198259 B2 JP5198259 B2 JP 5198259B2
- Authority
- JP
- Japan
- Prior art keywords
- oil
- viscosity
- additive
- composition
- mpas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 47
- 206010038848 Retinal detachment Diseases 0.000 title claims description 21
- 230000004264 retinal detachment Effects 0.000 title claims description 21
- 238000004519 manufacturing process Methods 0.000 title description 2
- 229920002545 silicone oil Polymers 0.000 claims description 63
- 239000000654 additive Substances 0.000 claims description 51
- 230000000996 additive effect Effects 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 14
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 12
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 239000003921 oil Substances 0.000 description 63
- 238000004945 emulsification Methods 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 14
- 239000003995 emulsifying agent Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 210000001525 retina Anatomy 0.000 description 11
- 239000012530 fluid Substances 0.000 description 9
- 229920001296 polysiloxane Polymers 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 4
- 229920001993 poloxamer 188 Polymers 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229910018503 SF6 Inorganic materials 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 2
- 229960004065 perflutren Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 2
- 229960000909 sulfur hexafluoride Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 101100477605 Arabidopsis thaliana SRT2 gene Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- -1 cyclic siloxanes Chemical class 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
シリコーンオイル内の乳化剤の生体外での形成を評価するための適当な方法を決定する実験を行った。次にこの方法を使って、より低い分子量のシリコーンオイルに、より高い分子量のシリコーンオイルを添加する効果を評価するための基礎研究の証明を行った。
次に1000mPasのシリコンオイルと高分子量の添加物の混合物に基づく組成物の剪断粘性および伸び粘性を評価し、この組成物が乳化を呈するかどうかを判断するための実験を行った。乳化剤としてプルロニック(Pluronic)F68またはタンパク質乳化剤を使用した。乳化剤の代わりに比較剤として精製水も使用した。
Claims (8)
- オイルと、このオイルの伸び粘性を高めることができる添加剤とを含み、
前記オイルはシリコーンオイル、ペルフルオロカーボンオイルまたは半弗素化アルカンオイルのうちの1つ以上から選択されたものであり、かつ5000mPas未満の粘性を有し、そして前記添加物は、シリコーンオイルであり、5,000〜25,000,000mPasの範囲内の粘度を有し、かつ組成物のうちの0.05〜20%w/wの範囲内の量存在する、網膜剥離の治療に使用するための液体組成物。 - 前記添加物は、組成物のうちの0.1〜5%w/wの範囲内の量存在する、請求項1に記載の組成物。
- オイルとこのオイルの伸び粘性を高めることができる添加剤とを混合するステップを含み、前記オイルはシリコーンオイル、ペルフルオロカーボンオイルまたは半弗素化アルカンオイルのうちの1つ以上から選択されたものであり、かつ5000mPas未満の粘性を有し、そして前記添加物は、シリコーンオイルであり、5,000〜25,000,000mPasの範囲内の粘度を有し、かつ組成物のうちの0.05〜20%w/wの範囲内の量存在する、網膜剥離の治療に使用するための組成物を製造する方法。
- 請求項1または2のうちのいずれかに記載の組成物を製造するために使用する、請求項3記載の方法。
- オイルとこのオイルの伸び粘性を高めることができる添加剤とを混合することを含む、網膜剥離の治療に使用するための組成物を製造するための部品のキットであって、第1の部品はオイルを含み、前記オイルはシリコーンオイル、ペルフルオロカーボンオイルまたは半弗素化アルカンオイルのうちの1つ以上から選択されたものであり、かつ5000mPas未満の粘性を有し、第2の部品はこのオイルの伸び粘性を高めることができる添加剤を含み、前記添加物は、シリコーンオイルであり、5,000〜25,000,000mPasの範囲内の粘度を有し、かつ組成物のうちの0.05〜20%w/wの範囲内の量存在する、キット。
- 請求項1または2のいずれかに記載の組成物を製造するために使用する、請求項5記載の部品のキット。
- オイルと添加物とを共に接触させ、使用前の混合物を形成する手段を更に含む、請求項5または6記載の部品のキット。
- 混合前に前記シリコーンオイルと前記添加物の所定の量を測定する手段を更に含む、請求項7記載の部品のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0510196.9 | 2005-05-19 | ||
GBGB0510196.9A GB0510196D0 (en) | 2005-05-19 | 2005-05-19 | Composition for treatment of a detached retina and method of production thereof |
PCT/EP2006/062432 WO2006122973A1 (en) | 2005-05-19 | 2006-05-18 | Composition for treatment of a detached retina and method of production thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008540607A JP2008540607A (ja) | 2008-11-20 |
JP5198259B2 true JP5198259B2 (ja) | 2013-05-15 |
Family
ID=34708415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008511711A Active JP5198259B2 (ja) | 2005-05-19 | 2006-05-18 | 網膜剥離を治療するための組成物およびその製造方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10363315B2 (ja) |
EP (1) | EP1881818B1 (ja) |
JP (1) | JP5198259B2 (ja) |
CN (1) | CN101180035B (ja) |
AU (1) | AU2006248902B2 (ja) |
CA (1) | CA2608571C (ja) |
GB (1) | GB0510196D0 (ja) |
HK (1) | HK1119394A1 (ja) |
HU (1) | HUE027852T2 (ja) |
PL (1) | PL1881818T3 (ja) |
PT (1) | PT1881818E (ja) |
SI (1) | SI1881818T1 (ja) |
WO (1) | WO2006122973A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0724226D0 (en) * | 2007-12-12 | 2008-01-23 | Univ Liverpool | Composition for the treatment of a detached retina and method of production thereof |
JP2013525028A (ja) | 2010-04-27 | 2013-06-20 | レンスゲン、インコーポレイテッド | 調節型眼内レンズ・デバイス |
WO2011140519A2 (en) | 2010-05-07 | 2011-11-10 | Medicus Biosciences, Llc | In vivo gelling pharmaceutical pre-formulation |
US10111985B2 (en) | 2011-08-10 | 2018-10-30 | Medicus Biosciences, Llc | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules |
US11083821B2 (en) | 2011-08-10 | 2021-08-10 | C.P. Medical Corporation | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules |
JP6206987B2 (ja) | 2012-05-11 | 2017-10-04 | メディカス バイオサイエンシーズ,エルエルシー | 網膜剥離の処置のための生体適合性ヒドロゲル製剤 |
EP2730291A1 (en) * | 2012-11-09 | 2014-05-14 | Fluoron Gmbh | Internal Tamponade Composition |
WO2014153038A1 (en) | 2013-03-14 | 2014-09-25 | Medicus Biosciences Llc | Biocompatible hydrogel polymer matrix for delivery of cells |
EP3062741B1 (en) | 2013-11-01 | 2023-04-26 | Lensgen, Inc. | Accomodating intraocular lens device |
WO2015066532A1 (en) | 2013-11-01 | 2015-05-07 | Daniel Brady | Two-part accommodating intraocular lens device |
US10004596B2 (en) | 2014-07-31 | 2018-06-26 | Lensgen, Inc. | Accommodating intraocular lens device |
GB201502565D0 (en) * | 2015-02-16 | 2015-04-01 | Alamedics Gmbh & Co Kg | Composition and use in treatment of a detached retina |
EP3383320A4 (en) | 2015-12-01 | 2019-08-21 | Lensgen, Inc | AKKOMODATIVE INTRAOCULAR LENS DEVICE |
CN109789012A (zh) | 2016-05-27 | 2019-05-21 | 雷恩斯根公司 | 用于眼内晶状体装置的具有窄分子量分布的晶状体油 |
ES2910987T3 (es) * | 2016-08-09 | 2022-05-17 | Univ Liverpool | Composiciones oftálmicas |
WO2018029476A1 (en) * | 2016-08-09 | 2018-02-15 | The University Of Liverpool | Ophthalmic compositions |
CN109833514A (zh) * | 2019-04-11 | 2019-06-04 | 上海杰视医疗科技有限公司 | 一种氟硅油的用途 |
DE202022105310U1 (de) | 2022-09-21 | 2022-10-18 | FLUORON GmbH Gesellschaft für hochreine Biomaterialien | Glaskörper-Tamponade |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1100931A (en) * | 1978-10-26 | 1981-05-12 | William C. Morro | Oil compositions containing high and low molecular weight poly(dimethylsiloxane) |
JP2506768B2 (ja) * | 1987-05-29 | 1996-06-12 | ポリプラスチックス株式会社 | ポリアセタ―ル樹脂組成物 |
US5391590A (en) * | 1993-01-12 | 1995-02-21 | Allergan, Inc. | Injectable intraocular lens compositions and precursors thereof |
US6135118A (en) | 1997-05-12 | 2000-10-24 | Dailey; James P. | Treatment with magnetic fluids |
US6703378B1 (en) * | 2002-09-19 | 2004-03-09 | Bausch & Lomb Incorporated | Vitreoretinal tamponades based on fluorosilicone fluids |
-
2005
- 2005-05-19 GB GBGB0510196.9A patent/GB0510196D0/en not_active Ceased
-
2006
- 2006-05-18 PT PT67552588T patent/PT1881818E/pt unknown
- 2006-05-18 CN CN2006800174149A patent/CN101180035B/zh active Active
- 2006-05-18 US US11/920,584 patent/US10363315B2/en active Active
- 2006-05-18 WO PCT/EP2006/062432 patent/WO2006122973A1/en not_active Application Discontinuation
- 2006-05-18 SI SI200631976T patent/SI1881818T1/sl unknown
- 2006-05-18 CA CA2608571A patent/CA2608571C/en active Active
- 2006-05-18 PL PL06755258T patent/PL1881818T3/pl unknown
- 2006-05-18 EP EP06755258.8A patent/EP1881818B1/en active Active
- 2006-05-18 HU HUE06755258A patent/HUE027852T2/en unknown
- 2006-05-18 AU AU2006248902A patent/AU2006248902B2/en not_active Ceased
- 2006-05-18 JP JP2008511711A patent/JP5198259B2/ja active Active
-
2008
- 2008-09-30 HK HK08110908.2A patent/HK1119394A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP1881818A1 (en) | 2008-01-30 |
CA2608571C (en) | 2015-04-21 |
HUE027852T2 (en) | 2016-11-28 |
EP1881818B1 (en) | 2015-07-29 |
AU2006248902B2 (en) | 2012-01-19 |
SI1881818T1 (sl) | 2015-10-30 |
HK1119394A1 (en) | 2009-03-06 |
WO2006122973A1 (en) | 2006-11-23 |
CN101180035A (zh) | 2008-05-14 |
CN101180035B (zh) | 2012-01-04 |
AU2006248902A1 (en) | 2006-11-23 |
JP2008540607A (ja) | 2008-11-20 |
PT1881818E (pt) | 2015-10-30 |
US20090170811A1 (en) | 2009-07-02 |
CA2608571A1 (en) | 2006-11-23 |
GB0510196D0 (en) | 2005-06-22 |
US10363315B2 (en) | 2019-07-30 |
PL1881818T3 (pl) | 2015-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5198259B2 (ja) | 網膜剥離を治療するための組成物およびその製造方法 | |
Barca et al. | Silicone oil: different physical proprieties and clinical applications | |
Chen et al. | Silicone oil in vitreoretinal surgery: indications, complications, new developments and alternative long‐term tamponade agents | |
CN104274487B (zh) | 清洗溶液 | |
Giordano et al. | Silicone oils as vitreous substitutes | |
Hoerauf et al. | Combined use of partially fluorinated alkanes, perfluorocarbon liquids and silicone oil: an experimental study | |
US20060090766A1 (en) | Surface modified viscoelastics for ocular surgery | |
US20050209606A1 (en) | Alginate viscoelastic composition, method of use and package | |
US20100323023A1 (en) | Composition for the treatment of a detached retina and method of production thereof | |
EP2730291A1 (en) | Internal Tamponade Composition | |
Williamson et al. | Principles of internal tamponade | |
WO2003059391A2 (en) | Viscoelastics for ocular surgery | |
US20040241155A1 (en) | Dilution resistant viscoelastic compositions | |
US20060003964A1 (en) | Dilution resistant viscoelastic compositions | |
Hammer et al. | Tolerance of perfluorocarbons, fluorosilicone, and silicone liquids in the vitreous | |
Arshinoff | Ophthalmic viscosurgical devices | |
Saxena et al. | Fluid vitreous substitutes in vitreo retinal surgery | |
EP3146959A1 (en) | Composition and use in treatment of a detached retina | |
Wong et al. | IV. G. Physiology of Vitreous Substitutes | |
Schepens | Vitreous substitutes and vitreous surgery | |
Donati et al. | Heavy and standard silicone oil: intraocular inflammation | |
WO2007008206A1 (en) | Dilution resistant viscoelastic compositions | |
Capone Jr et al. | Intravitreal use of perfluoro-n-octane in the management of retinal detachment with proliferative vitreoretinopathy | |
WO2008134616A2 (en) | Use of intravitreal viscosurgical injection agents for repair of rhegmatogenous (bullous) retinal detachment | |
Arshinoff | Routine cataract surgery, by phacoemulsification and intraocular lens implantation, is regarded as a quick, mature and relatively simple procedure. However, when the sequential steps of the procedure are |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120411 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121115 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20121128 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130206 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160215 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5198259 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |